Home > Haematology > First-line axi-cel therapy effective in high-risk large-B-cell lymphoma

First-line axi-cel therapy effective in high-risk large-B-cell lymphoma


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Nature Medicine
Reuters Health - 24/03/2022 - New research supports the use of axicabtagene ciloleucel (axi-cel) as first-line treatment for patients with high-risk large-B-cell lymphoma (LBCL). Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed/refractory LBCL after two or more systemic lines of therapy. In the phase-2 ZUMA-12 trial of 40 patients with high-risk LBCL, first-line axi-cel therapy led to a high objective response rate (89%) and complete response rate (78%). After a median follow up of 15.9 months, 73% of patients had an ongoing response. While the median duration of response, event-free survival and progression-free survival were not reached, 12-month estimates were 81%, 73% and 75%, respectively. The estimated overall survival rate at 12 months was 91%. Axi-cel therapy was well tolerated with no new safety signals. Grade-3-or-higher cytokine release syndrome (CRS) occurred in thr...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on